For the Inventor, By the Inventor

Enter assignee name

Irvine, CA, United States of America

Neomend, Inc.

USPTO Granted Patents = 27

% Expired Patents = 22.2

EPO Patents = 10

Trademarks = 1

Forward Citations = 2,371

Loading Chart...

Loading Chart...

23 inventors (with patents filed for the assignee):

Olexander Hnojewyj (14 out of 16 patents)

Gregory M Cruise (6 out of 9 patents)

William Jerome Mezger (5 out of 5 patents)

4. Theodore R Kucklick (5 out of 99 patents)

5. Theodore L Parker (5 out of 32 patents)

6. Charles F Milo (5 out of 48 patents)

7. Thomas C Wehman (5 out of 10 patents)

8. Stuart D Edwards (5 out of 118 patents)

9. Charles Vaughn Cassingham (4 out of 4 patents)

10. Ronald G Lax (4 out of 104 patents)

11. Bruce S Addis (4 out of 33 patents)

12. Eugene V Skalnyi (3 out of 21 patents)

13. Peter Gregory Davis (2 out of 38 patents)

14. Peter Barker, Jr (2 out of 3 patents)

15. Daniel Browne (2 out of 2 patents)

Core Competencies:

Wound Sealant

Hydrogel Compositions

Tissue Adhesion

Biocompatible Materials

Vascular Sealing

Centrifugal Mixing

Mechanical Barriers

Fluid Leakage Control

Suture Site Closure

Pleural Air Leak

Universal Introducer

Cross-Linked Compositions

27 patents: Sort by Forward Citations

1. 11571493 - Co-precipitation method (2023-02-07),

2. 10987093 - Method and apparatus for wound sealant application (2021-04-27),

3. 10300223 - Pleural air leak test system (2019-05-28),

4. 10144017 - Centrifugal mixing spray nozzle (2018-12-04),

5. 9662098 - Systems, devices, methods for delivering hydrogel compositions with self-purging to prevent clogging (2017-05-30),

6. 8802146 - Systems, methods, and compositions for prevention of tissue adhesion (2014-08-12),

7. 8642085 - Systems, methods, and compositions for prevention of tissue adhesion (2014-02-04),

8. 8641662 - Systems, devices, methods for delivering hydrogel compositions with self-purging to prevent clogging (2014-02-04),

9. 8409605 - Biocompatible material composition adaptable to diverse therapeutic indications (2013-04-02),

10. 8409249 - Systems, methods, and compositions for achieving closure of suture sites (2013-04-02),

11. 8383144 - Tissue adhering compositions (2013-02-26),

12. 8221452 - Systems and methods for sealing a vascular puncture (2012-07-17),

13. 8034367 - Tissue adhering compositions (2011-10-11),

14. 7351249 - Systems, methods, and compositions for achieving closure of suture sites (2008-04-01),

15. 7318933 - Systems, methods, and compositions for achieving closure of vascular puncture sites (2008-01-15),

Company Overview

Neomend, Inc. is a medical technology company based in Irvine, California, specializing in innovative solutions for wound care and surgical applications. The organization focuses on developing advanced biomaterials and products that enhance healing processes and improve patient outcomes. With a commitment to research and development, Neomend aims to address the evolving needs of healthcare professionals and patients, contributing to the advancement of medical practices in the field of regenerative medicine.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

27 Patents

#128 in Irvine, CA

#2,934 in California

#12,428 in US

#24,034 in the World

Irvine, CA, United States of America

Neomend, Inc.

Forward Citations = 2,371

23 inventors:

Olexander Hnojewyj (14 out of 16 patents)

Gregory M Cruise (6 out of 9 patents)

William Jerome Mezger (5 out of 5 patents)

4. Theodore R Kucklick (5 out of 99 patents)

5. Theodore L Parker (5 out of 32 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Neomend, Inc.. Retrieved from https://idiyas.com/company/neomend

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…